 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...449450451452453454455456457458459...522523» |
- | doxorubicin hydrochloride / generics
Journal: Injectable and self-healing polysaccharide-based hydrogel for pH-responsive drug release. (Pubmed Central) - Apr 11, 2019
...The pH-responsive behaviour was demonstrated by equilibrium swelling and in vitro Doxorubicin (Dox) release in PBS medium with various pH...In vitro degradation and cytotoxicity examinations showed that the hydrogel is biodegradable and biocompatible. Therefore, such polysaccharide-based injectable self-healing and pH-responsive hydrogel is a promising candidate as drug delivery carrier.
- | doxorubicin hydrochloride / generics
Journal: Dendrimer-Cationized-Albumin' encrusted polymeric nanoparticle improves BBB penetration and anticancer activity of doxorubicin. (Pubmed Central) - Apr 11, 2019
The outcomes of this investigation evidently indicate that dCatAlb-pDNP offers superior anticancer activity of DOX in glioblastoma cells while significantly improving its BBB permeation. The developed formulation is a biocompatible, safer and commercially viable approach to delivering DOX selectively in sustained manner glioblastoma while countering its hemolytic toxic effect, which is a major ongoing issue with conventional DOX injectable available in the market today.
- | doxorubicin hydrochloride / generics
Biomarker, Journal, Tumor microenvironment: SPIONs Embedded in Polyamino acid Nanogels to Synergistically Treat Tumor Microenvironment and Breast Cancer Cells. (Pubmed Central) - Apr 11, 2019
...Herein, a nanomedicine able to co-deliver doxorubicin and a tumor suppressive proteolytic protein such as collagenase-2 was developed...We demonstrated that a local ECM degradation and remodeling in solid tumors by means of collagenase-2 could enhance tumor penetration of nanomedicines and the in situ sustained release of the drug payload throughout 3-D tumor spheroids up to the core (parenchyma), thus enabling a synergistic and efficient anticancer effect toward highly invasive breast tumors. We illustrate that SPIONs/Doxo@Col is also capable of reducing the invasivity of cancer cells.
- | doxorubicin hydrochloride / generics
Journal: Effect of chitosan based glycolipid-like nanocarrier in prevention of developing acquired drug resistance in tri-cycle treatment of breast cancer. (Pubmed Central) - Apr 11, 2019
...In this research, a glycolipid-like nanocarrier encapsulating anti-tumor drug doxorubicin (DOX) was adopted to perform a long term drug stimulation in vitro cell line and a tri-cycle treatment on xenograft tumors to explore its effect in process of developing drug resistance...It concluded that tri-cycle therapy with the glycolipid-like nanocarrier would not result in acquired drug resistance. These results also implied that nano-drug delivery possessed ability in avoiding acquiring drug resistance ability during long-term treatment which may have potential use in clinic.
- | doxorubicin hydrochloride / generics
Journal: Novel quinoline derivatives carrying nitrones/oximes nitric oxide donors: Design, synthesis, antiproliferative and caspase-3 activation activities. (Pubmed Central) - Apr 11, 2019
...Compounds 6c, 6e, and 6f exhibited higher potency as anticancer agents compared to doxorubicin, with IC ranging from 0.45 to 0.91 μM...Compound 6e exhibited more pre-G1 apoptosis and cell cycle arrest at the G2/M phase than in other phases. These results revealed that the tested compounds can cause programmed cell death through overexpression of caspase 3, which may be attributed to the release of nitric oxide.
- | doxorubicin hydrochloride / generics
Journal: Pharmacological explorations of eco-friendly amide substituted (Z)-β-enaminones as anti-breast cancer drugs. (Pubmed Central) - Apr 11, 2019
The relative activities of 2a, 2b, and 2d of 84.56, 80.87, and 90.12%, respectively, were comparable to that of the standard, doxorubicin (82.16%). SAR studies demonstrated amide substituted (Z)-β-enaminones as precise PI3K inhibitors to treat breast cancer.
- | doxorubicin hydrochloride / generics
Journal: Effects of long noncoding RNA (linc-VLDLR) existing in extracellular vesicles on the occurrence and multidrug resistance of esophageal cancer cells. (Pubmed Central) - Apr 11, 2019
High expression of Linc-VLDLR and ABCG2 gene in esophageal cancer cells affected the formation of esophageal cancer drug resistance. EVs released by drug-resistant cells were proved that they could upregulate the expression of ABCG2 in esophageal cancer cells and thus regulate the drug resistance of esophageal cancer cells, which was related to the linc-VLDLR carried by EVs.
- | doxorubicin hydrochloride / generics
Journal: Engineering Polyzwitterion and Polydopamine Decorated Doxorubicin-Loaded Mesoporous Silica Nanoparticles as a pH-Sensitive Drug Delivery. (Pubmed Central) - Apr 11, 2019
More importantly, cellular uptake and in vitro anticancer activity tests suggested that MSNs-DOX@PDA-PSPP could be taken up by HepG2 cells and DOX could be successfully released and delivered into the cell nuclei. Taken together, MSNs@PDA-PSPP have great potential in the biomedical field.
- | doxorubicin hydrochloride / generics
Journal: Hypoxia-Responsive Mesoporous Nanoparticles for Doxorubicin Delivery. (Pubmed Central) - Apr 11, 2019
Confocal microscopy images indicated that DOX-CD-HR-MSNs effectively release DOX into SCC-7 cells under hypoxic conditions. These results demonstrate that CD-HR-MSNs can release drugs in a hypoxia-responsive manner, and thus are promising drug carriers for hypoxia-targeted cancer therapy.
- | paclitaxel / generics, doxorubicin hydrochloride / generics
Journal, Combination therapy: A Facile, One-Pot, Surfactant-Free Nanoprecipitation Method for the Preparation of Nanogels from Polyglycerolâ»Drug Conjugates that Can Be Freely Assembled for Combination Therapy Applications. (Pubmed Central) - Apr 11, 2019
Solubility of hydrophobic PTX was improved without the need for additional solubilizing agents such as polyethylene glycol (PEG). Interestingly, we found that our NGs made from PG-DOX conjugates have a high quenching efficiency for DOX, which could be interesting for theranostic purposes.
- | doxorubicin hydrochloride / generics
Journal: pH-Sensitive Micelles Based on Star Copolymer Ad-(PCL-b-PDEAEMA-b-PPEGMA)â‚„ for Controlled Drug Delivery. (Pubmed Central) - Apr 11, 2019
The DOX release study shows that the micelles are capable of controlled release for drug. This work indicates the Ad-(PCL-b-PDEAEMA-b-PPEGMA)â‚„ micelles may provide new guidelines for drug control and release system in overcoming cancer treatment.
- | doxorubicin hydrochloride / generics
Journal: Synthetic Glycopolypeptide Micelle for Targeted Drug Delivery to Hepatic Carcinoma. (Pubmed Central) - Apr 11, 2019
...In order to enhance the antitumor effect of doxorubicin (DOX), a glycopolypeptide-based micelle (GPM) modified by α-lactose (Lac) was synthesized for targeted treatment of hepatoma...Additionally, GPM/DOX exhibited a much higher drug accumulation in tumor tissue and a stronger antitumor effect in vivo than free DOX. The above results revealed that this drug delivery system provides a promising platform for the targeting therapy of hepatic cancer.
- | doxorubicin hydrochloride / generics
Journal: Intercellular transfer of P-glycoprotein mediates the formation of stable multidrug resistance in human bladder cancer BIU-87 cells. (Pubmed Central) - Apr 11, 2019
P-gp transfer between cells gradually increases with longer coculturing of drug-resistant and sensitive strains. The drug resistance of AqMDRs decreases without drug intervention, but with drug intervention, cells can maintain resistance and gradually develop into stable drug-resistant cells.
- | Arenegyr (NGR-hTNF) / Molmed
Clinical, P3 data, Journal, Combination therapy: NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. (Pubmed Central) - Apr 11, 2019
P3
The study did not meet its primary endpoint. The hypothesis-generating findings from the subgroup analyses deserve a confirmatory randomised trial because patients who rapidly progress after first-line treatment have a poor prognosis.
- | doxorubicin hydrochloride / generics
Clinical, Journal: Doxorubicin-Eluting Intra-arterial Therapy for Pediatric Extra-Abdominal Desmoid Fibromatoses: A Promising Approach for a Perplexing Disease. (Pubmed Central) - Apr 11, 2019
A single patient experienced transient lower extremity paresthesia (Common Terminology Criteria for Adverse Events grade I). Further investigation is needed to better establish these promising results for doxorubicin DEE in DF treatment.
- || Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed: Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib (clinicaltrials.gov) - Apr 11, 2019
P2, N=70, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Further investigation is needed to better establish these promising results for doxorubicin DEE in DF treatment. Recruiting --> Active, not recruiting
- || Imfinzi (durvalumab) / AstraZeneca
New P2 trial, Surgery: Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer (clinicaltrials.gov) - Apr 10, 2019
P2, N=24, Not yet recruiting, Sponsor: Stanford University
- | paclitaxel / generics, doxorubicin hydrochloride / generics
Review, Journal: Delivering Combination Chemotherapies and Targeting Oncogenic Pathways via Polymeric Drug Delivery Systems. (Pubmed Central) - Apr 10, 2019
Attempts to inhibit specific pathways for oncotherapy have also been described. These include inhibition of oncogenic pathways (including those involving HER2, EGFR, MAPK, PI3K/Akt, STAT3, and HIF-1α), augmentation of apoptosis by inhibiting anti-apoptosis proteins (Bcl-2, Bcl-xL, and survivin), and targeting dysregulated pathways such as Wnt/β-catenin and Hedgehog.
- | doxorubicin hydrochloride / generics
Journal, Combination therapy: A Polycationic Brush Mediated Co-Delivery of Doxorubicin and Gene for Combination Therapy. (Pubmed Central) - Apr 10, 2019
As a result, enhanced cell growth inhibition, with decreased DOX dosage was achieved due to the synergistic effect of co-delivery of DOX and the p53 gene. This finding provides an efficient approach for the development of a co-delivery system in combination therapy.
- | doxorubicin hydrochloride / generics
Journal: β-Cyclodextrinâ»Hyaluronic Acid Polymer Functionalized Magnetic Graphene Oxide Nanocomposites for Targeted Photo-Chemotherapy of Tumor Cells. (Pubmed Central) - Apr 10, 2019
...The β-cyclodextrin-hyaluronic acid polymers efficaciously enhance the doxorubicin (DOX) loading amount up to 485.43 mg·g...Significantly, the DOX-loaded nanocomposite (DOX@CDHAâ»MGO) has displayed CD44 receptor-mediated active targeting recognition and chemo-photothermal synergistic therapy of hepatoma cells. These findings suggest that the as-prepared drug delivery platform would be of valuable potential for cancer-targeted photo-chemotherapy.
- | doxorubicin hydrochloride / generics
Journal: Hyaluronic Acid-Decorated Laponite Nanocomposites for Targeted Anticancer Drug Delivery. (Pubmed Central) - Apr 10, 2019
In this study, hyaluronic acid (HA), a natural polysaccharide that can specifically bind to CD44 receptors, was conjugated onto laponite (LAP) nanodisks for the encapsulation and specific delivery of the anti-cancer drug doxorubicin (DOX) to CD44-overexpressed cancer cells...In addition, the flow cytometric detection and confocal laser scanning microscope results confirmed that LM-HA/DOX could be specifically internalized by HeLa cells via CD44-mediated endocytosis. Therefore, the HA-modified LAP nanodisks with high drug loading efficiency, pH-sensitive drug release properties and CD44 targetability might be an efficient nanoplatform for cancer chemotherapy.
- | doxorubicin hydrochloride / generics
Journal: Dual-responsive Gemini Micelles for Efficient Delivery of Anticancer Therapeutics. (Pubmed Central) - Apr 10, 2019
Further, the therapeutic effects of the DOX-loaded micelles were demonstrated using the KB cell line. This study shows that thiol and ROS dual-responsive gemini micelles are promising platforms for nano-drug delivery in various cancer therapies.
- | Nexavar (sorafenib) / Bayer, Amgen
Journal: Dual Drug Delivery of Sorafenib and Doxorubicin from PLGA and PEG-PLGA Polymeric Nanoparticles. (Pubmed Central) - Apr 10, 2019
The PLGA and PEG-PLGA polymers encapsulated doxorubicin with efficiencies of 52% and 69%, respectively, while these values for sorafenib were 55% and 88%, respectively. Sustained drug delivery under biorelevant conditions was found for doxorubicin, while sorafenib was released quickly from the PLGA-doxorubicin-sorafenib and PEG-PLGA-doxorubicin-sorafenib nanotherapeutics.
- | doxorubicin hydrochloride / generics
Journal: Self-Assembled Nanostructures of Red Fluorescent Amphiphilic Block Copolymers as Both Imaging Probes and Drug Carriers. (Pubmed Central) - Apr 10, 2019
Among the three types of polymers presented here, the polymer (RPO-3) containing an amorphous block of PDL showed the highest drug-loading capacity and the largest extent of drug release in acidic media. RPO-3 micelles loaded with doxorubicin as a model of anticancer drug showed sustainable intracellular release and cytotoxicity against HeLa cells.
- | doxorubicin hydrochloride / generics
Journal: Design, Synthesis, and Characterization of Schiff Base Bond-Linked pH-Responsive Doxorubicin Prodrug Based on Functionalized mPEG-PCL for Targeted Cancer Therapy. (Pubmed Central) - Apr 10, 2019
In vitro cytotoxicity assay tests revealed that the pH-sensitive DOX prodrug micelles exhibited relatively lower toxicity and similar antitumor efficacy towards MCF-7 cells compared with free DOX. Hence, the DOX prodrug micelles with imine bonds can offer a carrier with great potential for chemo-therapeutics.
- | doxorubicin hydrochloride / generics
Journal: ZnO Quantum Dots Modified by pH-Activated Charge-Reversal Polymer for Tumor Targeted Drug Delivery. (Pubmed Central) - Apr 10, 2019
Anti-cancer drug, Doxorubicin (DOX), molecules were demonstrated to be successfully loaded to ZnO@P(CBMA-co-DMAEMA) with a relatively large drug loading content (24.6%). In addition, ZnO@P(CBMA-co-DMAEMA) loaded with DOX can achieve lysosomal acid degradation and release of DOX after endocytosis by tumor cells, resulting in synergistic treatment of cancer, which is attributed to a combination of the anticancer effect of Zn and DOX.
- | doxorubicin hydrochloride / generics
Clinical, Retrospective data, Journal: Safety Profile and Efficacy of Chemoembolization with Doxorubicin - Loaded Polyethylene Glycol Microspheres in Patients with Hepatocellular Carcinoma. (Pubmed Central) - Apr 10, 2019
In addition, ZnO@P(CBMA-co-DMAEMA) loaded with DOX can achieve lysosomal acid degradation and release of DOX after endocytosis by tumor cells, resulting in synergistic treatment of cancer, which is attributed to a combination of the anticancer effect of Zn and DOX. The results from this investigation suggest that LifePearl microspheres, Terumo loaded with doxorubicin can provide an excellent local tumour control with very few side effects in a relatively homogeneous group of patients with locally untreatable HCC.
- | doxorubicin hydrochloride / generics
Journal: Mechanism of doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model. (Pubmed Central) - Apr 10, 2019
The results from this investigation suggest that LifePearl microspheres, Terumo loaded with doxorubicin can provide an excellent local tumour control with very few side effects in a relatively homogeneous group of patients with locally untreatable HCC. This study provides insight into the mechanisms of DOX induced cardiotoxicity and a framework for the development of future diagnostic and therapeutic strategies.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical, P2 data, Journal: Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. (Pubmed Central) - Apr 10, 2019
P2
Cohort B patients received four standard fluorouracil/epirubicin/cyclophosphamide cycles, then four docetaxel cycles with four standard trastuzumab and pertuzumab cycles...Treatment with pertuzumab, trastuzumab, and common anthracycline-containing regimens for the neoadjuvant treatment of early breast cancer resulted in cardiac and general safety profiles, and pCR rates, consistent with prior studies with pertuzumab. NCT02132949.
- | doxorubicin hydrochloride / generics, cyclophosphamide intravenous / generics
Biomarker, Clinical, Journal, BRCA Biomarker: Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with doxorubicin-based adjuvant chemotherapy (SWOG S9313). (Pubmed Central) - Apr 10, 2019
HRD status may identify TNBC patients who receive greater benefit from AC based chemotherapy and should be evaluated further in prospective studies. Int0137 (The trial pre-dates Clinicaltrial.Gov website establishment).
- | doxorubicin hydrochloride / Generic mfg.
New trial: TILA-TACE in Treatment of Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 10, 2019
P=N/A, N=2000, Recruiting, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
- | doxorubicin hydrochloride / generics
Journal: Improved chemotherapy against breast cancer through immunotherapeutic activity of fucoidan decorated electrostatically assembled nanoparticles bearing doxorubicin. (Pubmed Central) - Apr 9, 2019
Furthermore, pharmacokinetic study suggested that NPs administration in tumor infested mice caused serum DOX levels to vary in a biphasic pattern, with twin peaks occurring at 1 h and 6 h which help in maintaining preferential drug localization in tumor. Developed NPs would be an excellent approach for improved immune-chemotherapy (in terms of efficacy, safety and immunocompetency) against cancer.
- | doxorubicin hydrochloride / generics
Journal: Effect of SRC Kinase on Adriamycin Resistance and Invasion and Metastasis in Human Breast Cancer Cells (Pubmed Central) - Apr 9, 2019
The resistance of MCF-7 to ADM is accompanied by increased expression of SRC. SRC inhibitor PP2 can reduce the cell resistance, ability of invasion and metastasis.
- | doxorubicin hydrochloride / generics
Clinical, Journal, IO Biomarker: The long noncoding RNA LOC105374325 causes podocyte injury in individuals with focal segmental glomerulosclerosis. (Pubmed Central) - Apr 9, 2019
LOC105374325 overexpression decreased miR-34c and miR-196a/b levels, increased Bax and Bak levels, and induced proteinuria and focal segmental lesions in mice. In conclusion, the activation of the P38/C/EBPβ pathway stimulates the expression of LOC105374325, which, in turn, increases Bax and Bak levels and causes apoptosis by competitively binding to miR-34c and miR-196a/b in the podocytes of individuals with FSGS.
- | doxorubicin hydrochloride / generics
Journal: Cardiovascular Aggression by Doxorubicin: The Search for Mechanisms. (Pubmed Central) - Apr 9, 2019
In conclusion, the activation of the P38/C/EBPβ pathway stimulates the expression of LOC105374325, which, in turn, increases Bax and Bak levels and causes apoptosis by competitively binding to miR-34c and miR-196a/b in the podocytes of individuals with FSGS. No abstract available
- | doxorubicin hydrochloride / generics
Journal: Single crystal XRD, DFT investigations and molecular docking study of 2- ((1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)amino)naphthalene-1,4-dione as a potential anti- cancer lead molecule. (Pubmed Central) - Apr 9, 2019
Therefore DPDHN exhibited much higher toxicity towards MCF-7 cell lines. Thus, the results indicate that DPDHN is a potential anti cancer lead molecule especially for breast cancer studies.
- | doxorubicin hydrochloride / generics
Journal: Spinochrome D Attenuates Doxorubicin-Induced Cardiomyocyte Death via Improving Glutathione Metabolism and Attenuating Oxidative Stress. (Pubmed Central) - Apr 9, 2019
With SpD treatment, the mitochondrial membrane potential and mitochondrial calcium localization were significantly different between cardiomyocytes and cancer cell lines. Our findings suggest that SpD could be cardioprotective against the cytotoxicity of doxorubicin.
- | doxorubicin hydrochloride / generics
Journal: A Pharmacological Strategy Using Stemofoline for more Efficacious Chemotherapeutic Treatments Against Human Multidrug Resistant Leukemic Cells (Pubmed Central) - Apr 9, 2019
Our findings suggest that SpD could be cardioprotective against the cytotoxicity of doxorubicin. ...a combination treatment of STF and doxorubicin (DOX) in vitro and in vivo...These findings supportour previous in vitro data and indicate the possibility of developing STF as an adjuvant therapy in cancer treatments.
- | doxorubicin hydrochloride / generics
Review, Journal: Current state of the art and emerging pharmacotherapy for uterine leiomyosarcomas. (Pubmed Central) - Apr 9, 2019
...In the case of advanced, persistent, or recurrent ULMS, chemotherapy is the standard care with the most frequently used drug being doxorubicin...Recently, pazopanib, and olaratumab, two innovative targeted drugs, have been approved by the Food and Drug Administration (FDA) for treating advanced soft-tissue sarcoma, including ULMS. However, further clinical investigations into new and innovation therapeutic options are warranted.
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS
New P3 trial, Metastases: SWOG S1826: Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma (clinicaltrials.gov) - Apr 9, 2019
P3, N=987, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | cyclophosphamide / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
New trial: Alpha-Lipoic Acid in Breast Cancer Patients (clinicaltrials.gov) - Apr 8, 2019
P=N/A, N=50, Recruiting, Sponsor: Damanhour University
- | Trial completion date, Trial primary completion date: COC-IDCB: A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast (clinicaltrials.gov) - Apr 8, 2019
P1, N=300, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
However, further clinical investigations into new and innovation therapeutic options are warranted. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
- | Rituxan (rituximab) / Roche, Calquence (acalabrutinib) / AstraZeneca
Phase classification, Trial primary completion date: ACCEPT: A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov) - Apr 8, 2019
P1/2, N=39, Recruiting, Sponsor: University Hospital Southampton NHS Foundation Trust
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2020 Phase classification: P2 --> P1/2 | Trial primary completion date: Dec 2018 --> Aug 2019
- | paclitaxel / generics, doxorubicin hydrochloride / generics
Journal: Recombinant synthesis of hybrid lipid-peptide polymer fusions that self-assemble and encapsulate hydrophobic drugs. (Pubmed Central) - Apr 7, 2019
Their lipid cores can be loaded with hydrophobic small molecules by passive diffusion. Encapsulated doxorubicin and paclitaxel exhibit cytotoxic effects on 4T1 and PC3-luc cells, respectively, with potencies similar to chemically conjugated counterparts, and longer plasma circulation than free drug upon intravenous injection in mice.
- | doxorubicin hydrochloride / generics
Journal: Remote Loading of Small Molecule Therapeutics into Cholesterol-Enriched Cell Membrane-Derived Vesicles. (Pubmed Central) - Apr 7, 2019
The therapeutic implications of these naturally derived, remote-loaded nanoformulations are studied both in vitro and in vivo using animal disease models. Ultimately, this approach could be used to design new biomimetic nanoformulations with higher efficacy and improved safety profiles.
- | doxorubicin hydrochloride / generics
Journal, Video: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Procedure for Non-resectable Peritoneal Carcinomatosis (with Video). (Pubmed Central) - Apr 7, 2019
This video protocol provides a better understanding of the PIPAC procedure and the safety measures essential for this method of chemotherapy administration. It should help all teams wishing to implement a PIPAC therapy program.
- | doxorubicin hydrochloride / generics
Preclinical, Journal: Mitochondrial targeted doxorubicin-triphenylphosphonium delivered by hyaluronic acid modified and pH responsive nano-carriers to breast tumor: in vitro and in vivo studies. (Pubmed Central) - Apr 7, 2019
Our results showed HA-hydra-DOX-TPP to self-assemble to core/shell nanoparticles of good dispersibility and effective release of DOX-TPP from the HA-hydra-DOX-TPP conjugate in cancer cells which was followed by enhanced DOX mitochondria accumulation. The HA-hydra-DOX-TPP nanoparticles also showed improved anti-cancer effects, induced better tumor cell apoptosis and a better safety profile compared to free DOX in MCF-7/ADR bearing mice.
- | doxorubicin hydrochloride / generics
Journal: Targeting of G-Quadruplex Harboring Pre-miRNA 92b by LNA Rescues PTEN Expression in NSCL Cancer Cells. (Pubmed Central) - Apr 7, 2019
This strategy can be developed as a novel anti-pre-miRNA therapeutic approach to target GQ harboring miRNAs. This can potentially be a more powerful approach than targeting of the mature miRNA, as it is an upstream targeting and can reduce both 3' and the 5' mature miRNA levels at once.
- | cisplatin / generics, doxorubicin hydrochloride / generics
Biomarker, Journal: Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1. (Pubmed Central) - Apr 7, 2019
In addition, functional assays revealed that circPVT1 knockdown by siRNA could weaken the resistance to doxorubicin and cisplatin of OS cells through decreasing the expression of classical drug resistance-related gene ABCB1. These findings may provide a new insight into the role of circPVT1 as a biomarker for the diagnosis and treatment target of OS.
- | doxorubicin hydrochloride / generics
Journal: The effect of adjuvant therapy with TNF-α on animal model of triple-negative breast cancer. (Pubmed Central) - Apr 7, 2019
The accumulation of Dox was even higher when systemically injected with a micellar formulation of Dox. This work provides a rationale for testing the combination on breast cancer patients.